Surgeon‑Patient’s Battle with Prior Authorisation

A surgeon who has led a top joint‑replacement centre finds himself on the other side of the healthcare maze when he is diagnosed with a slow‑growing brain tumour.

He shows how the system that was meant to stop waste can, in practice, become a maze that delays treatment and hurts patients.

While researching the problem for his own patients, he discovered that only a small fraction of denied prior authorisations are ever upheld – yet the paperwork burden is huge.

When he needed a genetic test to see if his tumour’s mutation could be inherited, the insurer denied it outright. He had to fight back, using a peer‑to‑peer review that he himself performed, and the test was finally approved. Most patients lack this skill or support.

The same hurdles appeared when he began a new drug that costs about $30,000 per month. A routine insurance plan change triggered a denial; after an appeal the pharmacy was only allowed to refill for 15 days, leaving him drug‑free for two days – a gap that could have real health consequences.

These delays are not limited to cancer; patients waiting for joint replacements can also face weeks or months of uncertainty. The system places the administrative load on doctors’ offices, who must now employ extra staff just to manage denials.

Legislation can help. Pennsylvania’s 2024 law requires insurers to publish prior‑authorization policies online and bans the process for emergency care, though enforcement is weak. On the national stage, a bipartisan Medicare‑related bill has stalled because of cost projections that may actually raise overall spending.

The author argues for clear, evidence‑based reasons for every denial and for automatic approval of FDA‑approved treatments that have strong data. He believes no patient should choose between fighting disease and battling paperwork.